Ion channels : functional expression and therapeutic potential in cancer
Ion channels: functional expression and therapeutic potential in cancer Colloquium on Ion Channels and Cancer Scott P. Fraser1 & Luis A. Pardo2 Neuroscience Solutions to Cancer Research Group, Division of Cell and Molecular Biology, Imperial College London, London SW7 2AZ, UK Abteilung Molekulare Biologie Neuronaler Signale, Max-Planck-Institut für Experimentelle Medizin, Hermann-Rein-Strasse 3, 37075 Göttingen, Germany Björn Nordenström has utilized concepts in physics, mathematics, chemistry, physiology and immunology; combined with a massive amount of experimentation; to describe a system of continuous energy circulation and circulating electrical currents in living systems. Living cells consist of ions, charged molecules, membranes and organelles, which are responsive to electrical fields and currents and sometimes even generate electrical activity. When a non-uniform electric field is generated near living cells, polar molecules will move towards the higher field intensity. When an altering current is generated the molecules stay in place, their reaction being only vibration. However, in dividing cells the altering field causes the molecules to move towards the furrow, which is the narrow place between the two daughter cells. Using this principle the scientists had a way to tell apart normal cells from dividing cells, which are normally cancerous cells. Biologically Closed Electric Circuits, Björn EW Nordenström, MD, (Nordic Medical Publications, Arsenalsgatan 4, S …
Video Rating: 5 / 5
Visit our website: www.adultgeriatrics.com Or listen at 7AM on Saturdays on WSBR740AM. Bad breath, or halitosis, is a very common problem that can be embarrassing and make one self-conscious. There are many people with halitosis of various ages as bad breath and the associated bacteria can occur in almost any mouth. Your dentist can help cure this problem by offering a treatment program for bad breath. What Causes Bad Breath? Studies have shown that bad breath typically begins when the waste produced by bacteria in the mouth, nose or stomach comes into contact with the air. Nasal dysfunction such as a genetic abnormality in the nasal passage may inhibit proper mucus flow. The bacteria found in sinusitis (inflammation of the sinuses), post-nasal drip, and allergies may flow from the nose to the back of the tongue where it can lie dormant due to improper saliva flow or poor dental hygiene. The bacteria that grows on the gums and between the teeth can lead to halitosis, tooth decay and gum disease (periodontics). Biologists have found that there are numerous types of bacteria that contribute to halitosis that are present in other unpleasant odors, including the following: corpse scent (a combination of oxygen and sulfur compounds and/or nitrogen-containing gases such as cadaverine) decayed meat (putrescine) rotten egg stench (hydrogen sulfide) smelly feet (isovaleric acid) feces aroma (methyl mercaptan and skatole) Who is Most Susceptible to Bad Breath? Those who have poor …
JVZoo Product Feed
Categories: Videos Tags: expression, therapeutic, channel's, cancer, potential, functional
First therapeutic vaccine for advanced lung cancer registered in the world
First therapeutic vaccine for advanced lung cancer registered in the world
Article by Pablo Martin ROdriguez
Between 1980 and 2008, the mortality rate from lung cancer in women has doubled. Each year it is seen a growth of 1.7%, while among men the rate is being reduced by 2%. Today, 28.6% of women aged 18 to 64 years and is estimated that 7.6 million people died just 2008 due to lung cancer, a number that it is expected to increased to eleven million in 2030.
It is quite possible that two of the biggest concerns of health-related the citizens express in any country in the world are AIDS and cancer. Although there are other diseases that have less “press” and charge a huge amount of victims every year, especially in tropical regions, the truth is that getting a vaccine effective against cancer or AIDS are among the main objectives of laboratories around the world.
Fortunately, the battle against lung cancer has won a new step: it is a therapeutic vaccine rather than preventive, developed by recombinant technology advanced lung cancer, CimaVax-EGF, that was created in Cuba by scientists at the Molecular Immunology Center Havana.
This Cuban drug was prepared after 15 years of research and is currently being administered in 65 health centers in Cuba and have taken steps necessary to register in Brazil, Argentina, Colombia and several other nations.
According to Cuban experts, the drug can not prevent disease but to control advanced cancer to generate antibodies against proteins that trigger the uncontrolled cell proliferation processes.
It consists of a therapeutic tool that is part of the field of immunotherapy, in which it is intended that the patient’s immune system triggers an effective response to control the growth of tumors.The vaccine is composed of epidermal growth factor protein and P-64 K of the membrane, obtained by recombinant means. The vaccine was successfully applied to more than 1000 patients in Cuba, where his health record was held in June 2008.
The result is that the vaccine extends survival time of patients, but does not prevent or cure lung cancer.
Specialists described the vaccine as “very promising” that soon others will come into being tested in China and will open doors in Asia. Is also expected next clinical trial in countries like Australia, Thailand, Malaysia and Britain.
According to Gonzalez (the proyect leader) they are still workings with the principle of this vaccine with the intent to use in developing therapies against other tumors such as prostate, uterus and breast cancer.
About the Author
Pablo Rodriguez is a freelance writer and medical researcher. He has written multiples articles about cancer and spefically mesothelioma. He is currently studying a writer career at University of Buenos Aires.
If you want to read more about the first vaccine for lung cancer click the link
Related Lung Tumor Articles
JVZoo Product Feed
Categories: Articles Tags: lung, world , first, therapeutic, cancer, advanced, vaccine, registered
Met signaling pathway as a novel therapeutic target
Met signaling pathway as a novel therapeutic target
Article by Katewinslet
The cytoskeleton plays a key role in oncogenesis because of its implication in the division, growth and adhesion of cells, as well as its motility and invasion. Therefore, oncogenes have been showed the interact with the cytoskeleton during the process of the generation and development of a variety of cancers. These genes include v-src, v-crk, and BCR/ABL, as well as E6. Considering MET specifically, it influence the motility of cell by modifying the polymerization and depolymerization of actin, as well as the formation of stress fiber.
The signaling transduction pathway contains MET phosphorylation of the cytoskeletal proteins paxillin, p125FAK and Pyk2. For example, the signaling pathway may interpret why small cell lung cancer cells have enhanced motility after the stimulation of human growth factor. Among the many cytoskeletal proteins, paxillin may be especially important because it interacts with the cytoskeleton after its activation by MET signaling. It stands at the crossroads of several molecular signaling transduction pathways, helping tointegrate diverse signals promoting adhesion, growth, and motility, as well as actin reorganization and regulation of gene expression. Elevated expression has been observed in various of non-small cell tumors, while the concentraions of paxillin are often low or absent in small-cell tumors. In one study, high expression of paxillin was noted in fifty one percent of large cell tumors, thirty three percent of adenocarcinomas, and twenty three percent of squamous cell.
Meanwhile, the paxillin level also associated with disease stage and was particularly high in metastatic samples. Lots of these non-small cell lines had raised numbers of gene copies for both paxillin and MET, indicating an important mechanism underlying these elevated paxillin levels. In addition to numeric increase, mutations also expand paxillin’s influences. The overall rate of paxillin mutation in lung cancer is discovered to be nine point four percent and is particularly high in non-small cell cancers, with eighteen point four percent of large cell carcinomas bearing a mutation.[1] Now, Met is considered to be a therapeutic target. And the small molecular compounds including PHA665752, XL 880, XL184, ARQ197, SGX523, MGCD265 are the targeted-met signaling inhibitors. The price of these inhibitors provided by different companies is varied as well as purification and quality.
References:[1] Cell Adh Migr. 2010 Jan-Mar;4(1):146-52
Related posts:
The safety and tolerability of XL184 (cabozantinib) in phase I clinical trials
The therapeutic roles of XL184 (cabozantinib) in medullary thyroid carcinoma (MTC)
About the Author
Buy inhibitors for research work. Well known by scientists and researchers worldwide for enzastaurin perifosine, PF-02341066, Pomalidomide, raltegravir and other inhibitors.If you would like to get more specific information about some life research product like Fingolimod , Lenalidomide ,Revlimid etc than you can check the link list bottom of this page or visit directly to http://www.selleckchem.com.
Find More Non Small Cell Carcinoma Articles
JVZoo Product Feed
The possible results for combined therapeutic strategies for tumors
The possible results for combined therapeutic strategies for tumors
Article by Katewinslet
The phenomena of tumor resistance may contribute to some mechanisms. For example, several lines of evidence suggest that multiple receptor tyrosine kinases are concomitantly activated in the same type of tumor. Therefore, prevention of one of these receptors might have relatively constricted influences at certain degree if the other receptor tyrosine kinases go on maintaining the transduction of downstream pro-oncogenic signaling. On the other hand, it might also be contrary, triggering compensatory elevation of the associated proteins or receptors in parallel, alternative signaling circuits.
There are several lines of evidence that this does indeed happen. Lung tumors with activating EGFR mutations usually respond to agents that block this receptor tyrosine kinase, including gefitinib and elotinib, but the response is invariably temporary. It has been indicated that the tumor’s later resistance to these drugs stems from parallel magnification of MET following consequent activation of PI3K/Akt cell survival signaling pathway.
Definitely, the experimental inhibition of MET signaling transduction signaling in lung cancer cell lines restores their susceptibility to gefitinib. In good line with these results, it is reported that inhibition of VEGF signaling can really motivate the spread of tumor in animal models. In addition, the expression of MET was found, more than once, to be up-regulated after selective prevention of VEGF signaling pathway, and the invasiveness and metastasis of tumor decreased when both VEGF and MET tyrosine kinases were suppressed. These data enhance the possibility of compensatory signaling in response to the inhibition of a single receptor tyrosine kinases. Moreover, these results also highlight the key role of MET kinase activity in the invasiveness of tumor. Conceivably, any anti-angiogenic treatment could result in the amplification of MET tyrosine kinase.[1]
AEE788 is a potent dual inhibitor of human epidermal receptor (HER) 1/2 and vascular endothelial growth factor receptor (VEGFR) 1/2. In vitro, AEE788 prevented cell proliferation (IC50 from 1.7 to 3.8 µM) and inhibited epidermal growth factor- and neuregulin-induced HER1, HER2, and HER3 activation. Suppresssion of Akt paralleled that of HER receptors. In vivo, AEE788 inhibited Daoy, DaoyPt, and DaoyHER2 xenografts by 51%, 45%, and 72%, respectively. AEE788 blocks one of the most crucial pathways in cancer cell growth: the epidermal growth factor (EGF) receptor-tyrosine kinase pathway. AEE788 may also reduce the growth of new blood vessels. In addition, as shown in Fig.1, AEE788 blocks the activation of NRG-dependent HER3. On binding to NRG, the “kinase dead” HER3 dimerizes with other HER receptors, preferably HER2, functioning as a scaffold to activate the PI3K/Akt pathway because of having multiple p85/p110a docking sites. NRG strongly activated the HER3/PI3K/Akt route in D283 cells that display high levels of endogenous HER2, but it did not do so in DaoyHER2 cells.
References:[1] Nat Rev Mol Cell Biol. 2010 Dec;11(12):834-48.
Related posts:
Introduction of a set of Flt-3 inhibitors
The therapeutic roles of XL184 (cabozantinib) in medullary thyroid carcinoma (MTC)
Side effects caused by the therapy of EGFR inhibitors
Comparison of chemical and biological characterizations of a series of EGFR inhibitors
About the Author
Buy inhibitors for research work. Well known by scientists and researchers worldwide for enzastaurin Masitinib, Neratinib, Olaparib,panobinostat and other inhibitors.If you would like to get more specific information about some life research product like Fingolimod , Lenalidomide ,Revlimid etc than you can check the link list bottom of this page or visit directly to http://www.selleckchem.com.
More Lung Tumor Articles
JVZoo Product Feed
Categories: Articles Tags: results, tumors , possible, combined, therapeutic, strategies
Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical
Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical
Article by Bharatbook
Bharatbook added a new report on ” Lung Cancer Therapeutic Antibodies: Pipeline, Strategies and Clinical ” which gives an overview, Demand, Supply Trends and industry analysis reports.This report provides a comprehensive review of 27 candidate that are being evaluated for the treatment of ; covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 potential targets.
Globally, is the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that -care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.
Patient needs and the high burden of on society drive the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing approaches, are urgently required
Today, developments continue to be made in drug treatments for ; in chemotherapy, new drug combinations, and targeted molecules. In particular, advances are being seen in the field of immunotherapy; in the development of new and therapeutic vaccines.
This Report
This report (see brochure) provides a comprehensive review of and reviews R&D and clinical developments in the treatment of as the primary indication, as well as studies that are evaluating cancer alongside other cancers.
Today, more than 25 candidate therapeutic antibodies are in development or are being evaluated for the treatment of , most of which are already in clinical trials. This field is also showing substantial innovation and these molecules are being directed at 17 different targets. This report gives an overview of the status and clinical findings of these candidate vaccines, together with developmental and market-related perspectives in this field.
Key content:
• Late-stage (Phases 2/3, 3 and Approved, n = 4) pipeline and companies• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 23) pipeline and companies• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting , Phase 1, 1/2 and 2• Drug targets being targeted by from preclinical through to Phase 3, and Approved• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phase 1-3) of being evaluated for the treatment of • Summaries of clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses) reported following clinical trials (Phase 1-3) of being evaluated for the treatment of • Commercial partnerships and collaborations on pipeline therapeutic antibodies• Drug combination strategies in the evaluation of the targeting of • A comprehensive listing of salient details of clinical trials of being evaluated for the treatment of • Technical and market insights and perspectives in the development and clinical evaluation of the treatment of • Competitive and market-related information
Tables
• 1.1 Global incidence and mortality from lung cancer, 2008• 1.2 NSCLC survival rates, according to cancer stage• 1.3a Five-year relative cancer survival rates in the USA for white males• 1.3b Five-year relative cancer survival rates in the USA for white females• 1.4 US national expenditure on different cancers (2006)• 1.5 US lost productivity due to different cancer types in the US, 2005• 2.1 Approved/late-stage candidate the treatment of • 3.1 Early-stage being developed or evaluated for the treatment of lung cancer or for /other cancers• 4.1 Other (largely antibody-related) therapies being developed or evaluated for the treatment of lung cancer or other cancers• 5.1 Approved/late-stage being developed for the treatment of lung cancer• 5.2 Early-stage candidate being developed or evaluated for the treatment of lung cancer or for other cancers• 5.3 Other (primarily antibody-related) therapies in development or being evaluated for lung cancer or for other cancers• 5.4 Approved/candidate the treatment of for lung cancer/other cancers• 5.5 Other candidate therapies (primarily antibody-related) for the treatment of lung cancer or for other cancers• 5.6 NSCLC survival rates, according to cancer stage
Figures
• 3.1 Early-stage pipeline therapeutic antibodies for the treatment of lung cancer or other cancers• 5.4 Approved and pipeline being developed or evaluated for the treatment of lung cancer or for lung/other cancers• 5.6 Other (primarily antibody-related) early-stage candidate therapies in development or being evaluated for lung cancer/other cancers• 5.10 Organisations developing or evaluating lung cancer therapeutic antibodies• 5.12 Clinical trials of the treatment of lung cancer or lung cancer/other cancers, involving single or combination agents
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=213744&rt=Lung-Cancer-Therapeutic-Antibodies-Pipeline-Strategies-and-Clinical.html
Or
Contact us at :
Bharat Book BureauTel: +91 22 27578668 / +91 22 27579438Fax: +91 22 27579131Email: info@bharatbook.comWebsite: http://www.bharatbook.com
About the Author
Bharat Book Bureau, the leading market research information aggregator provides company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.
JVZoo Product Feed
Categories: Articles Tags: clinical , therapeutic, pipeline, cancer, antibodies, strategies, lung
Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical, 2011
Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical, 2011
Article by Bharatbook
Bharatbook added a new report on ” Lung Cancer Vaccines and Therapeutic Antibodies: Pipeline, Strategies and Clinical, 2011 ” which gives an overview, Demand, Supply Trends and industry analysis reports.This report provides a comprehensive review of 27 candidate therapeutic antibodies and 42 candidate vaccines that are being evaluated for the treatment of covering pipeline, disease-targeting strategies and clinical findings. These antibodies are directed at 17 targets, while the vaccines are directed at 24 antigens or antigen combinations.
Globally, the most common cancer and in 2008 there were an estimated 1.6 million new cases and 1.4 million deaths (almost 20% of all cancer deaths) caused by this disease. Five-year survival rates are also low (15-20%) compared to other common cancers. In the US, studies have shown that lung cancer-care costs (in 2006) were the third highest of all cancers, while indirect costs (2005) were higher than for any other cancer.
Patient needs and the high burden of are driving the development of new therapies. While improvements have been seen in diagnosis and treatments (surgery, radiotherapy, chemotherapy and targeted drugs), new therapies that build on the capabilities of existing strategies, are urgently required. Today, advances continue to be made in drug treatments for chemotherapy, new drug combinations and targeted molecules. In particular, advances are being seen in the field of immunotherapy, in the development of new therapeutic antibodies and therapeutic vaccines.
This Report
This report provides a comprehensive review of lung cancer immunotherapy. With a focus on therapeutic vaccines and antibodies, it reviews R&D and clinical developments in the treatment of as the primary indication, as well as studies that are evaluating lung cancer alongside other cancers. It provides a comprehensive review of pipeline developments, therapeutic strategies and clinical findings, covering therapeutic vaccines and antibodies.
Today, around 70 immunotherapies are being developed or evaluated for the treatment of lung cancer. This report reviews developments on 27 candidate therapeutic antibodies and 42 candidate vaccines for treating most of which are in clinical development.
The immunotherapy pipeline is showing substantial innovation and many new strategies are being evaluated. Today’s pipeline of therapeutic antibodies are directed at 17 drug targets. On the vaccine front, 24 different antigen/multiple antigen targeting strategies are being investigated. For the purpose of this report, multiple antigen targeting vaccines have been treated as single targeting strategies.
More than 90% of the immunotherapy candidates in development or being evaluated for treating are identified in this report, are in clinical development. This report gives an overview of the status and clinical findings of these candidate therapies. It also gives developmental and market-related perspectives in this rapidly developing field.
Key content:
• Late-stage (Phases 2/3, 3 and Approved, n = 4) therapeutic antibodies and companies• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 23) therapeutic antibodies and companies• Late-stage (Phases 2/3, 3 and Approved, n = 5) vaccines and companies• Early-stage (Preclinical and Phases 1, 1/2 and 2, n= 37) vaccines and companies• Other (mainly antibody related, n=6) candidate therapies in the development pipeline for targeting hases 1, 1/2 and 2• Drug targets against which therapeutic antibodies are being directed, from preclinical through to Phase 3, and Approved• Antigen/antigen combinations being targeted by vaccines, from preclinical through to Phase 3, and Approved• Descriptions of clinical trials (patients and numbers, conditions, treatments, regimens, Phases 1-3) of therapeutic antibodies and vaccines being evaluated for the treatment of lung cancer• Summaries of the clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses), following clinical trials (Phases 1-3) of therapeutic antibodies being evaluated for the treatment of lung cancer• Summaries of the clinical status and clinical findings (safety, adverse events and multiple event-related clinical responses), following clinical trials (Phases 1-3) of vaccines being evaluated for the treatment of lung cancer• Commercial partnerships and collaborations on pipeline therapeutic antibodies and vaccines• Drug combination strategies in the evaluation of therapeutic antibodies and vaccines for targeting• A comprehensive listing of salient details of clinical trials of therapeutic antibodies and vaccines being evaluated for the treatment of lung cancer• Technical and market insights and perspectives in the development and clinical evaluation of therapeutic antibodies and vaccines for the treatment of lung cancer• Competitive and market-related information
For more information kindly visit : http://www.bharatbook.com/detail.asp?id=213740&rt=Lung-Cancer-Vaccines-and-Therapeutic-Antibodies-Pipeline-Strategies-and-Clinical-2011.html
Or
Contact us at :
Bharat Book BureauTel: +91 22 27578668 / +91 22 27579438Fax: +91 22 27579131Email: info@bharatbook.comWebsite: http://www.bharatbook.com
About the Author
Bharat Book Bureau, the leading market research information aggregator provides company profiles, country reports, newsletters, and online databases for the past twenty four years to corporate, consulting firms, academic institutions, government departments, agencies etc., globally, including India. Our market research reports help global companies to know different market before starting up business / expanding in different countries across the world.
Find More Survival Rate Lung Cancer Articles
JVZoo Product Feed
Categories: Articles Tags: vaccines, pipeline, antibodies, clinical, therapeutic, cancer, 2011 , strategies, lung
UM researchers discover therapeutic target that could help patients with pulmonary fibrosis
More than 40000 people die each year from idiopathic pulmonary fibrosis, a condition with no effective treatment. Now, researchers at the University of Michigan have discovered a therapeutic target in mice that could lead to treatment for patients.
Video Rating: 5 / 5
JVZoo Product Feed
Categories: Videos Tags: therapeutic, pulmonary, discover, help, target, fibrosis, could, researchers, patient's
Various breast cancer treatments to achieve the best therapeutic effect
Various breast cancer treatments to achieve the best therapeutic effect
Article by mouzhe
Early discovery and diagnosis of the mammary carcinoma is very important, and has becomes the key point of treating effect and prognosis. At present, suggest use of biological therapy adjuvant treat with Surgery, radiation therapy, chemotherapy, comprehensive breast cancer treatment. Various cancer treatments to make up a deficiency, make the treatment to achieve the best therapeutic effect.
Breast Cancer Surgery, Recent studies show that the breast conservation surgery is the main model for treating stage ?and ? of breast cancer. If the cancer surgery can completely clear the lesions, the patients have access to health and survival, But breast may be out of sharpa after surgery if the procedure is inappropriate. It will make the cancer tissues to be injury and blood loss. It is easy to cause the cancer recurrence, proliferation and metastasis. If the patient can accept the biological treatment in time to improve the diet and the patients sleep, Enhance physical fitness. It is beneficial to the recurrence and metastasis.
Breast cancer chemotherapy and breast-conserving therapy are the two main treatment of early breast cancer. The cancer chemotherapy is often used to treat breast cancer in stage ? or cancer metastasis as systemic treatment. Breast cancer chemotherapy can effectively kill cancer cells, at the same time can also kill the Normal human cells. The Cancer Chemotherapy, Chemotherapy is commonly used in the treatment of cancer. Chemotherapy also kills the healthy stem cells in the marrow. The strong drugs used in chemotherapy cause a number of toxic side effects because it kills healthy cells as well as cancerous ones. Destroys rapidly-growing healthy cells in the bone marrow, gastro-intestinal tract etc, and can cause organ damage, like liver, kidneys, heart, lungs etc. Cancer treatments today tend to be less harsh. Surgery is less disfiguring, chemotherapy less disabling.
Dendritic cell(DC) is the most powerful antigen-presenting cell in human body. It is the major antigen-presenting cell in innate immunity and play an important role in cancer suppresion. cytokine induced killer(CIK) is the lymphocyte, present in human blood, after a certain time to develop an immune active cells. Many young women appear such symptoms of breast pain, breast color change, Immune system is taken seriously more and more in the body against tumors. The breast cancer treatment Immunotherapy is called the fourth cancer treatment modality for this.
Medical workers in their study found that Chinese medicine can be resumed leukemia cells to chemotherapy sensitivity. It plays an important role in preventing and treating chemotherapy-induced emesis, especially in delayed emesis. TCM combinated interventional chemotherapy on Advanced primary hepatic cancer is a kind of safe and effective methods, and is worthy to be spreaded in clinic practice
About the Author
Breast cancer alert distant Treatment of breast cancer metastasis of cancer cells. http://www.cancer-c.com is a new star of Cancer Rehabilitation Website it will be to provide the latest information about Traditional Chinese Medicine(TCM) Breast cancer chemotherapy
JVZoo Product Feed
Categories: Articles Tags: cancer, various, breast, therapeutic, best, achieve, treatments, effect
Could “eugenol” be used as a therapeutic agent in asbestosis?
Question by Paul H: Could “eugenol” be used as a therapeutic agent in asbestosis?
“Eugenol” is a chemical found in an extract of cloves, nutmeg, vanilla, and cinnamon that polymerizes to asbestos fibers, neutralizing their toxicity. If administered via positive-pressure breathing apparatus or hyperbaric chamber therapy could it have a potential effect on people suffering from asbestosis?
Best answer:
Answer by huggz
I doubt it as its the damage the asbestos causes to the cells which causes the asbestosis, not just the asbestos itself. So even if it were possible to remove the fibres the cells would still be severely damaged;
Know better? Leave your own answer in the comments!
JVZoo Product Feed
Categories: Answers Tags: could, used, asbestosis, agent, therapeutic, eugenol
